BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat […]
Tag: Jacobio Pharma
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, […]
